Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: A systematic review

British Journal of Dermatology

Volumn 168, Issue 2, 2013, Pages 243-252

  Blok, Janine L ^a   Van Hattem, S ^a   Jonkman, M F ^a   Horvath B ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; COLCHICINE; CYCLOSPORIN A; DAPSONE; ERYTHROMYCIN; ETANERCEPT; ETRETIN; ETRETINATE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISOTRETINOIN; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; RETINOID; USTEKINUMAB;

ABSCESS; ADD ON THERAPY; ALOPECIA; ANAPHYLACTIC SHOCK; ANEMIA; ARTHRALGIA; ARTHRITIS; ASTHENIA; BILIRUBIN BLOOD LEVEL; CELLULITIS; CHEILITIS; CHOLESTEROL BLOOD LEVEL; COLON CANCER; CYSTITIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRY EYE; DRY SKIN; DYSPNEA; EMBASE; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HAY FEVER; HEMOLYSIS; HERPES ZOSTER; HOARSENESS; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; LUPUS LIKE SYNDROME; MAINTENANCE THERAPY; MALAISE; MEDLINE; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUROPATHY; PARESTHESIA; PHOTOSENSITIVITY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PSORIASIS; PUSTULE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; REVIEW; SEPSIS; SIDE EFFECT; SKIN IRRITATION; STAPHYLOCOCCUS INFECTION; SUPPURATIVE HIDRADENITIS; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; THORAX PAIN; TINNITUS; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; UTERINE CERVICITIS; VIRUS REACTIVATION; XEROSIS;

ADULT; AGED; BIOLOGICAL AGENTS; DERMATOLOGIC AGENTS; EVIDENCE-BASED MEDICINE; HIDRADENITIS SUPPURATIVA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; RETINOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872910847     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12104     Document Type: Review

References (113)

1. Alikhan A, Lynch PJ, Eisen DB,. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60: 539-61; quiz 562-3.
2. Jemec GB, Revuz J, Leyden J,. Hidradenitis Suppurativa. Berlin: Springer-Verlag, 2006.
3. Matusiak L, Bieniek A, Szepietowski JC,. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol 2010; 62: 706-8.
4. Wolkenstein P, Loundou A, Barrau K, et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56: 621-3.
5. Jemec GB,. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012; 366: 158-64.
6. Rambhatla PV, Lim HW, Hamzavi I,. A systematic review of treatments for hidradenitis suppurativa. Arch Dermatol 2012; 148: 439-46.
7. Haslund P, Lee RA, Jemec GB,. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol 2009; 89: 595-600.
8. Attanoos RL, Appleton MA, Douglas-Jones AG,. The pathogenesis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands. Br J Dermatol 1995; 133: 254-8.
9. von Laffert M, Stadie V, Wohlrab J, Marsch WC,. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol 2011; 164: 367-71.
10. Jemec GB, Hansen U,. Histology of hidradenitis suppurativa. J Am Acad Dermatol 1996; 34: 994-9.
11. Sellheyer K, Krahl D,. 'Hidradenitis suppurativa' is acne inversa! An appeal to (finally) abandon a misnomer. Int J Dermatol 2005; 44: 535-40.
12. Nazary M, van der Zee HH, Prens EP, et al. Pathogenesis and pharmacotherapy of hidradenitis suppurativa. Eur J Pharmacol 2011; 672: 1-8.
13. Schlapbach C, Hanni T, Yawalkar N, Hunger RE,. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011; 65: 790-8.
14. Matusiak L, Bieniek A, Szepietowski JC,. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol 2009; 89: 601-3.
15. van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011; 164: 1292-8.
16. Wolk K, Warszawska K, Hoeflich C, et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol 2011; 186: 1228-39.
17. Robinson JK, Dellavalle RP, Bigby M, Callen JP,. Systematic reviews: grading recommendations and evidence quality. Arch Dermatol 2008; 144: 97-9.
18. Brunasso AM, Massone C,. Rotational therapy with TNF-alpha blockers for recalcitrant hidradenitis suppurativa. Eur J Dermatol 2010; 20: 644-6.
19. van Rappard DC, Leenarts MF, Meijerink-van't Oost L, Mekkes JR,. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat 2012; 23: 284-9.
20. Amano M, Grant A, Kerdel FA,. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol 2010; 49: 950-5.
21. Arenbergerova M, Gkalpakiotis S, Arenberger P,. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy. Int J Dermatol 2010; 49: 1445-9.
22. Harde V, Mrowietz U,. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab. J Dtsch Dermatol Ges 2009; 7: 139-41.
23. Blanco R, Martinez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol 2009; 145: 580-4.
24. Gorovoy I, Berghoff A, Ferris L,. Successful treatment of recalcitrant hidradenitis suppurativa with adalimumab. Case Rep Dermatol 2009; 1: 71-7.
25. Sotiriou E, Apalla Z, Vakirlis E, Ioannides D,. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa. Eur J Dermatol 2009; 19: 180-1.
26. Yamauchi PS, Mau N,. Hidradenitis suppurativa managed with adalimumab. J Drugs Dermatol 2009; 8: 181-3.
27. Moul DK, Korman NJ,. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol 2006; 142: 1110-12.
28. Scheinfeld N,. Treatment of coincident seronegative arthritis and hidradenitis suppurativa with adalimumab. J Am Acad Dermatol 2006; 55: 163-4.
29. Alzaga Fernandez AG, Demirci H, Darnley-Fisch D, Steen DW,. Interstitial keratitis secondary to severe hidradenitis suppurativa: a case report and literature review. Cornea 2010; 29: 1189-91.
30. Koilakou S, Karapiperis D, Tzathas C,. A case of hidradenitis suppurativa refractory to anti-TNFα therapy in a patient with Crohn's disease. Am J Gastroenterol 2010; 105: 231-2.
31. Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol 2011; 165: 391-8.
32. van der Zee HH, Laman JD, de Ruiter L, et al. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol 2012; 166: 298-305.
33. Adams DR, Yankura JA, Fogelberg AC, Anderson BE,. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 2010; 146: 501-4.
34. Lee RA, Dommasch E, Treat J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2009; 60: 565-73.
35. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008; 158: 567-72.
36. Zangrilli A, Esposito M, Mio G, et al. Long-term efficacy of etanercept in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2008; 22: 1260-2.
37. Cusack C, Buckley C,. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006; 154: 726-9.
38. Henderson RL Jr,. Case reports: treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept. J Drugs Dermatol 2006; 5: 1010-11.
39. Sotiriou E, Apalla Z, Ioannidos D,. Etanercept for the treatment of hidradenitis suppurativa. Acta Derm Venereol 2009; 89: 82-3.
40. Lopez-Martin C, Tortajada Goitia B, Faus Felipe V, et al. Partial response to etanercept in the treatment of hidradenitis suppurativa. Farm Hosp 2011; 35: 189.e1-4.
41. Pelekanou A, Kanni T, Savva A, et al. Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial. Exp Dermatol 2010; 19: 538-40.
42. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-17.
43. van Rappard DC, Mekkes JR,. Treatment of severe hidradenitis suppurativa with infliximab in combination with surgical interventions. Br J Dermatol 2012; 167: 206-8.
44. Delage M, Samimi M, Atlan M, et al. Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers. Acta Derm Venereol 2011; 91: 169-71.
45. Brunasso AM, Delfino C, Massone C,. Hidradenitis suppurativa: are tumour necrosis factor-α blockers the ultimate alternative? Br J Dermatol 2008; 159: 761-3.
46. Mekkes JR, Bos JD,. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008; 158: 370-4.
47. Fernandez-Vozmediano JM, Armario-Hita JC,. Infliximab for the treatment of hidradenitis suppurativa. Dermatology 2007; 215: 41-4.
48. Usmani N, Clayton TH, Everett S, Goodfield MD,. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol 2007; 32: 204-5.
49. de Souza A, Solomon GE, Strober BE,. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bull NYU Hosp Jt Dis 2011; 69: 185-7.
50. Dos Santos CH, Netto PO, Kawaguchi KY, et al. Association and management of Crohn's disease plus hidradenitis suppurativa. Inflamm Bowel Dis 2011; 18: E801-2.
51. von Preussen AC, Flux K, Hartschuh W, Hartmann M,. Acne inversa successfully treated with infliximab. Int J Dermatol 2011; 58: 507-8.
52. Husein-ElAhmed H, Fernandez-Pugnaire MA, Ruiz-Carrascosa JC,. Severe hidradenitis suppurative in an HIV-positive male: use of multiple treatment modalities, including tumor necrosis factor blockade. AIDS Patient Care STDS 2011; 25: 507-8.
53. Alecsandru D, Padilla B, Izquierdo JA, et al. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab. Arch Dermatol 2010; 146: 1343-5.
54. Lasocki A, Sinclair R, Foley P, Saunders H,. Hidradenitis suppurativa responding to treatment with infliximab. Australas J Dermatol 2010; 51: 186-90.
55. Poulin Y,. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept. J Cutan Med Surg 2009; 13: 221-5.
56. Antonucci A, Negosanti M, Negosanti L, et al. Acne inversa treated with infliximab: different outcomes in 2 patients. Acta Derm Venereol 2008; 88: 274-5.
57. Elkjaer M, Dinesen L, Benazzato L, et al. Efficacy of Infliximab treatment in patients with severe Fistulizing Hidradenitis Suppurativa. J Crohns Colitis 2008; 2: 241-5.
58. Montes-Romero JA, Callejas-Rubio JL, Sánchez-Cano D, et al. Amyloidosis secondary to hidradenitis suppurativa. Exceptional response to infliximab. Eur J Intern Med 2008; 19: e32-3.
59. Pedraz J, Penas PF, Garcia-Diez A,. Pachyonychia congenita and hidradenitis suppurativa: no response to infliximab therapy. J Eur Acad Dermatol Venereol 2008; 22: 1500-1.
60. Goertz RS, Konturek PC, Naegel A, et al. Experiences with a long-term treatment of a massive gluteal acne inversa with infliximab in Crohn's disease. Med Sci Monit 2009; 15: CS14-18.
61. Kwan C, Chong L,. A Chinese man with chronic recalcitrant hidradenitis suppurativa successfully treated with infliximab. Hong Kong J Dermatol Venereol 2008; 16: 206-10.
62. Moschella SL,. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol 2007; 46: 1287-91.
63. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007; 56: 624-8.
64. Thielen AM, Barde C, Saurat JH,. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol 2006; 155: 1105-7.
65. Rosi YL, Lowe L, Kang S,. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat 2005; 16: 58-61.
66. Mekkes J, Hommes D,. Treatment of suppurative hidradenitis with surgical deroofing and infliximab. Ned Tijdschr Dermatol Venereol 2004; 14: 196-7.
67. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD,. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 2003; 139: 1540-2.
68. Sullivan TP, Welsh E, Kerdel FA, et al. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003; 149: 1046-9.
69. Lebwohl B, Sapadin AN,. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2003; 49: S275-6.
70. Roussomoustakaki M, Dimoulios P, Chatzicostas C, et al. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol 2003; 38: 1000-4.
71. Katsanos KH, Christodoulou DK, Tsianos EV,. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol 2002; 97: 2155-6.
72. Martinez F, Nos P, Benlloch S, Ponce J,. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001; 7: 323-6.
73. van Rappard DC, Mooij JE, Baeten DL, Mekkes JR,. New-onset polyarthritis during successful treatment of hidradenitis suppurativa with infliximab. Br J Dermatol 2011; 165: 194-8.
74. Torres T, Selores M,. Treatment of hidradenitis suppurativa with infliximab. An Bras Dermatol 2010; 85: 576.
75. Garcia-Rabasco AE, Esteve-Martinez A, Zaragoza-Ninet V, et al. Pyoderma gangrenosum associated with hidradenitis suppurativa: a case report and review of the literature. Actas Dermosifiliogr 2010; 101: 717-21.
76. Lozeron P, Denier C, Lacroix C, Adams D,. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009; 66: 490-7.
77. Obadia DL, Daxbacher EL, Jeunon T, Gripp AC,. Hidradenitis suppurativa treated with infliximab. An Bras Dermatol 2009; 84: 695-7.
78. Deschamps ME, Payet S, Tournadre A, et al. Efficacy of infliximab in the treatment of follicular occlusion triad. Ann Dermatol Venereol 2010; 137: 546-50.
79. Pedraz J, Dauden E, Perez-Gala S, et al. Hidradenitis suppurativa. Response to treatment with infliximab. Actas Dermosifiliogr 2007; 98: 325-31.
80. Benitez-Macias J, Garcia-Gil D, Brun-Romero F,. Fatal pneumococcal sepsis in a patient with hidradenitis suppurativa treated with infliximab. Med Clin 2008; 131: 799.
81. Maalouf E, Faye O, Poli F, et al. Fatal epidermoid carcinoma in hidradenitis suppurativa following treatment with infliximab. Ann Dermatol Venereol 2006; 133: 473-4.
82. Suys E, D'Heygere F,. Infliximab for acne inversa (alias hidradenitis suppurativa)? Ned Tijdschr Dermatol Venereol 2005; 15: 406-7.
83. Gulliver WP, Jemec GB, Baker KA,. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2012; 26: 911-14.
84. Sharon VR, Garcia MS, Bagheri S, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol 2012; 8: 320-1.
85. Soria A, Canoui-Poitrine F, Wolkenstein P, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients' outcome assessment. Dermatology 2009; 218: 134-5.
86. Boer J, van Gemert MJ,. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol 1999; 40: 73-6.
87. Dicken CH, Powell ST, Spear KL,. Evaluation of isotretinoin treatment of hidradenitis suppurativa. J Am Acad Dermatol 1984; 11: 500-2.
88. Norris JF, Cunliffe WJ,. Failure of treatment of familial widespread hidradenitis suppurativa with isotretinoin. Clin Exp Dermatol 1986; 11: 579-83.
89. Fearfield LA, Staughton RC,. Severe vulval apocrine acne successfully treated with prednisolone and isotretinoin. Clin Exp Dermatol 1999; 24: 189-92.
90. Jones DH, Cunliffe WJ, King K,. Hidradenitis suppurativa-lack of success with 13-cis-retinoic acid. Br J Dermatol 1982; 107: 252.
91. Brown CF, Gallup DG, Brown VM,. Hidradenitis suppurativa of the anogenital region: response to isotretinoin. Am J Obstet Gynecol 1988; 158: 12-15.
92. Boer J, Nazary M,. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol 2011; 164: 170-5.
93. Chow ET, Mortimer PS,. Successful treatment of hidradenitis suppurativa and retroauricular acne with etretinate. Br J Dermatol 1992; 126: 415.
94. Hogan DJ, Light MJ,. Successful treatment of hidradenitis suppurativa with acitretin. J Am Acad Dermatol 1988; 19: 355-6.
95. Scheman AJ,. Nodulocystic acne and hidradenitis suppurativa treated with acitretin: a case report. Cutis 2002; 69: 287-8.
96. Stewart W,. Etretinate in other diseases of keratinization. In: The Retinoids, a Significant Advance in Dermatology (Hoffmann-La Roche Limited, ed.). Oxford: Medicines Publishing Foundation Symposium Series, 1984; 51-5.
97. Vahlquist A, Griffiths W,. Retinoid therapy in hidradenitis suppurativa-a report of a case. Retinoids Today Tom 1990; 18: 28-30.
98. Yazdanyar S, Boer J, Ingvarsson G, et al. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology 2011; 222: 342-6.
99. Kaur MR, Lewis HM,. Hidradenitis suppurativa treated with dapsone: a case series of five patients. J Dermatolog Treat 2006; 17: 211-13.
100. Hofer T, Itin PH,. Acne inversa: a dapsone-sensitive dermatosis. Hautarzt 2001; 52: 989-92.
101. van der Zee HH, Prens EP,. The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa. Dermatology 2011; 223: 169-73.
102. Rose RF, Goodfield MJ, Clark SM,. Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin. Clin Exp Dermatol 2006; 31: 154-5.
103. Buckley DA, Rogers S,. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med 1995; 88: 289P-90P.
104. Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990; 126: 339-50.
105. Jemec GB,. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol 2002; 27: 528-9.
106. van Rappard DC, Limpens J, Mekkes JR,. The off-label treatment of severe hidradenitis suppurativa with TNF-alpha inhibitors: a systematic review. J Dermatolog Treat 2012; [Epub ahead of print]. doi: 10.3109/09546634.2012.674193.
107. von Laffert M, Stadie V, Wohlrab J, Marsch WC,. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol 2011; 164: 367-71.
108. Laffert MV, Helmbold P, Wohlrab J, et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010; 19: 533-7.
109. Jemec GB, Gniadecka M,. Sebum excretion in hidradenitis suppurativa. Dermatology 1997; 194: 325-8.
110. Rigopoulos D, Larios G, Katsambas AD,. The role of isotretinoin in acne therapy: why not as first-line therapy? Facts and controversies. Clin Dermatol 2010; 28: 24-30.
111. Dispenza MC, Wolpert EB, Gilliland KL, et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012; 132: 2198-205.
112. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; 2: CD008794.
113. Katz HI, Waalen J, Leach EE,. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999; 41: S7-12.